Gland Pharma Limited
GLAND
Classifica tra le azioni
#3270
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Prezzo delle azioni
$32.70
Capitalizzazione di mercato
$5.40B
Variazione (1 giorno)
-1.88%
Variazione (1 anno)
49.71%
Paese
IN
Scambia Gland Pharma Limited (GLAND)
Categoria
Healthcare
Utile per Gland Pharma Limited (GLAND)
Utile nel Jun 2026 TTM: $175.12M
Secondo gli ultimi rapporti finanziari di Gland Pharma Limited, gli utili attuali della società sono $175.12M. Nel 2024, la società ha registrato un utile di $135.82M, un aumento rispetto a agli utili del 2023, che erano di $128.32M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Gland Pharma Limited dal 2017 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $175.12M | 40.94% |
| 2025 | $124.25M | -8.52% |
| 2024 | $135.82M | 5.84% |
| 2023 | $128.32M | -39.82% |
| 2022 | $213.22M | 16.94% |
| 2021 | $182.34M | 38.35% |
| 2020 | $131.79M | 33.35% |
| 2019 | $98.83M | 28.32% |
| 2018 | $77.02M | -13.59% |
| 2017 | $89.13M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 907.63% |
IN
|
